Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
immunomodulatory treatment
outcome measures
relapsing-remitting MS
treatment
treatment response
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
19
08
2021
accepted:
13
12
2021
pubmed:
21
12
2021
medline:
5
4
2022
entrez:
20
12
2021
Statut:
ppublish
Résumé
Treatment success in relapsing-remitting multiple sclerosis (RRMS) is generally determined using relapse frequency and magnetic resonance imaging (MRI) activity in the first 6 or 12 months on treatment. The association of these definitions of short-term treatment success with disability worsening and disease activity in the longer term is unclear. In this study, we investigated risk factors associated with early first-line treatment failure in RRMS, and the association of early treatment failure with subsequent disability worsening or "no evidence of disease activity" (NEDA-3) status. We used data from CombiRx (clinicaltrials.gov identifier NCT00211887) to investigate risk factors associated with early treatment failure, and the association of early treatment failure at 6 and 12 months with subsequent disability worsening or NEDA-3 at 36 months. CombiRx included 1008 treatment-naïve participants with RRMS, who were randomly assigned to treatment with glatiramer acetate, interferon beta, or the combination of both. Early treatment failure at 6 or 12 months by several definitions was associated with NEDA-3 failure at 36 months, but not with subsequent disability worsening at 36 months. Expanded Disability Status Scale (EDSS) was the only baseline characteristic associated with the risk of disability worsening at 36 months. Approximately 70% of NEDA-3 failures occurred due to MRI activity, and <10% occurred due to EDSS worsening. Our investigation shows that current definitions of early treatment failure in RRMS are unrelated to patient-relevant disability worsening at 36 months of follow-up. Further research into useful definitions of treatment success and failure in RRMS is needed.
Sections du résumé
BACKGROUND AND PURPOSE
Treatment success in relapsing-remitting multiple sclerosis (RRMS) is generally determined using relapse frequency and magnetic resonance imaging (MRI) activity in the first 6 or 12 months on treatment. The association of these definitions of short-term treatment success with disability worsening and disease activity in the longer term is unclear. In this study, we investigated risk factors associated with early first-line treatment failure in RRMS, and the association of early treatment failure with subsequent disability worsening or "no evidence of disease activity" (NEDA-3) status.
METHODS
We used data from CombiRx (clinicaltrials.gov identifier NCT00211887) to investigate risk factors associated with early treatment failure, and the association of early treatment failure at 6 and 12 months with subsequent disability worsening or NEDA-3 at 36 months.
RESULTS
CombiRx included 1008 treatment-naïve participants with RRMS, who were randomly assigned to treatment with glatiramer acetate, interferon beta, or the combination of both. Early treatment failure at 6 or 12 months by several definitions was associated with NEDA-3 failure at 36 months, but not with subsequent disability worsening at 36 months. Expanded Disability Status Scale (EDSS) was the only baseline characteristic associated with the risk of disability worsening at 36 months. Approximately 70% of NEDA-3 failures occurred due to MRI activity, and <10% occurred due to EDSS worsening.
CONCLUSIONS
Our investigation shows that current definitions of early treatment failure in RRMS are unrelated to patient-relevant disability worsening at 36 months of follow-up. Further research into useful definitions of treatment success and failure in RRMS is needed.
Substances chimiques
Glatiramer Acetate
5M691HL4BO
Interferon-beta
77238-31-4
Banques de données
ClinicalTrials.gov
['NCT00211887']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1106-1116Subventions
Organisme : NINDS NIH HHS
ID : U01 NS045719
Pays : United States
Informations de copyright
© 2021 European Academy of Neurology.
Références
Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169-180. doi:10.1056/NEJMra1401483
Kaunzner UW, Al-Kawaz M, Gauthier SA. Defining disease activity and response to therapy in MS. Curr Treat Options Neurol. 2017;19(5):20. doi:10.1007/s11940-017-0454-5
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-340. doi:10.1002/ana.23863
Lindsey JW, Scott TF, Lynch SG, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord. 2012;1(2):81-86. doi:10.1016/j.msard.2012.01.006
Lublin FD, Cofield SS, Cutter GR, et al. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: efficacy and safety results up to 7 years. Mult Scler Relat Disord. 2017;18:95-102. doi:10.1016/j.msard.2017.09.012
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231. doi:10.1002/ana.410130302
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
Motl RW, Cohen JA, Benedict R, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):704-710. doi:10.1177/1352458517690823
Feys P, Lamers I, Francis G, et al. The Nine-Hole Peg test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017;23(5):711-720. doi:10.1177/1352458517690824
Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260. doi:10.1016/S1474-4422(09)70021-3
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2021. http://www.R-project.org/
Coyle PK, Reder AT, Freedman MS, Fang J, Dangond F. Early MRI results and odds of attaining “no evidence of disease activity” status in MS patients treated with interferon β-1a in the EVIDENCE study. J Neurol Sci. 2017;379:151-156. doi:10.1016/j.jns.2017.05.052
Koch MW, Mostert J, Greenfield J, Liu W-Q, Metz L. Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent. J Neurol. 2020;267(9):2619-2624. doi:10.1007/s00415-020-09895-0
Tortorella C, Bellacosa A, Paolicelli D, et al. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J Neurol Sci. 2005;239(1):95-99. doi:10.1016/j.jns.2005.08.006
Koch MW, Mostert J, Uitdehaag B, Cutter G. Clinical outcome measures in SPMS trials: an analysis of the IMPACT and ASCEND original trial data sets. Mult Scler. 2020;26(12):1540-1549. doi:10.1177/1352458519876701
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. doi:10.1056/NEJMoa1601277
Sajja BR, Datta S, He R, et al. Unified approach for multiple sclerosis lesion segmentation on brain MRI. Ann Biomed Eng. 2006;34(1):142-151. doi:10.1007/s10439-005-9009-0
Goodin DS, Reder AT, Traboulsee AL, et al. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019;25(6):837-847. doi:10.1177/1352458518773511
Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016;22(10):1297-1305. doi:10.1177/1352458515616701
Guevara C, Villa E, Diaz V, et al. Inclusion of the symbol digit modalities test in a revised assessment of “no evidence of disease activity-4 (NEDA-4)” in Latin-American patients with multiple sclerosis. Mult Scler Relat Disord. 2020;42:102076. doi:10.1016/j.msard.2020.102076
Prosperini L, Mancinelli C, Haggiag S, et al. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(3):271-277. doi:10.1136/jnnp-2019-322348
Sormani MP, Rio J, Tintorè M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19(5):605-612. doi:10.1177/1352458512460605
Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016;87(2):134-140. doi:10.1212/WNL.0000000000002830